Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aratana Therapeutics, Inc. (NASDAQ: PETX).

Full DD Report for PETX

You must become a subscriber to view this report.


Recent News from (NASDAQ: PETX)

Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference
LEAWOOD, Kan. , Aug. 29, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans on presenting at CL King & Associates Best Ideas Con...
Source: PR Newswire
Date: August, 29 2018 08:30
The latest portfolio moves by Engaged Capital
Engaged Capital updates on its portfolio holdings as of the end of Q2. More news on: Universal Electronics Inc., Casey's General Stores, Inc., Groupon, Inc., Consumer stocks news, Tech stocks news, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 15:26
Factors of Influence in 2018, Key Indicators and Opportunity within GTT Communications, Hope, Black Knight, Safety Insurance Group, M.D.C., and Aratana Therapeutics - New Research Emphasizes Economic Growth
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GTT Communications, Inc. (NYSE:GTT), Hope Bancorp, Inc. (NASDAQ:HOPE), Bl...
Source: GlobeNewswire
Date: August, 07 2018 08:20
Q2 Update On Aratana Therapeutics
Coffee is a way of stealing time that should by rights belong to your older self .” ― Terry Pratchett, Thud! Small cap veterinary drug concern Aratana Therapeutics ( PETX ) posted second quarter earnings results last week. After an initial dip post-earnings, the stock r...
Source: SeekingAlpha
Date: August, 07 2018 08:09
Aratana Therapeutics (PETX) CEO Steven St. Peter on Q2 2018 Results - Earnings Call Transcript
Aratana Therapeutics (PETX) Q2 2018 Results Earnings Conference Call August 3, 2018, 08:30 AM ET Executives Rachel Reiff - Corporate Communications Steven St. Peter - President and CEO Craig Tooman - CFO Analysts Jon Block - Stifel Sriker Nadipuram - Barclays Swayampaku...
Source: SeekingAlpha
Date: August, 03 2018 12:54
Aratana Therapeutics beats by $0.05, misses on revenue
Aratana Therapeutics (NASDAQ: PETX ): Q2 EPS of -$0.14 beats by $0.05 . More news on: Aratana Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 02 2018 17:00
Aratana Therapeutics Reports Second Quarter 2018 Financial Results
LEAWOOD, Kan. , Aug. 2, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second quarter 2018 financial results. For the se...
Source: PR Newswire
Date: August, 02 2018 16:05
Aratana Therapeutics to Report Second Quarter 2018 Financial Results
LEAWOOD, Kan. , July 10, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, August 3, 2018 a...
Source: PR Newswire
Date: July, 10 2018 08:30
Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks
Stock Research Monitor: AIMT, PETX, and ABIO LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ALKS sign up now at www.wallstequities.com/registration . Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT ), ...
Source: ACCESSWIRE IA
Date: June, 19 2018 07:05
Has A New Advaxis Awakened Out Of The Doldrums?
Author's note: Subscribers to the Total Pharma Tracker gained early access to this article. Another quarter, another Advaxis ( ADXS ) analysis. Looking at the chart for the entire year so far, you could perhaps be forgiven in forgetting that anything happened at all aside from the diluti...
Source: SeekingAlpha
Date: June, 08 2018 16:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-085.225.245.335.21116,689
2018-05-175.515.575.605.4853207,025
2018-01-115.255.295.37865.25462,029
2018-01-105.065.255.285.0568330,206
2018-01-095.055.115.114.942,425,694

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1326,94057,87946.5454Short
2018-12-1215,04029,30051.3311Short
2018-12-1112,67340,94530.9513Cover
2018-12-1020,25750,84939.8376Short
2018-12-0722,77260,73237.4959Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PETX.


About Aratana Therapeutics, Inc. (NASDAQ: PETX)

Logo for Aratana Therapeutics, Inc. (NASDAQ: PETX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: PETX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 01 2018
      Amendment to a previously filed 10-K
      Filing Type: 10-K/AFiling Source: edgar
      Filing Date: April, 27 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: April, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 05 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 14 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 13 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: PETX)

      Daily Technical Chart for (NASDAQ: PETX)


      Stay tuned for daily updates and more on (NASDAQ: PETX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: PETX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PETX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PETX and does not buy, sell, or trade any shares of PETX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/